Filing Flows › Comparisons › IMNM vs KYNB
Immunome vs Kyntra Bio: IMNM and KYNB compared
Immunome is the larger company: $4.0M of revenue in its latest quarter (Q2 2025) against $3.7M for Kyntra Bio (Q1 2026). Immunome is growing faster (+70% against +36% a year earlier).
Where the money goes: IMNM and KYNB
Immunome (IMNM) · Q2 2025
Immunome, Q2 2025: revenue $4.0M (+70% year over year), net loss $43.4M, operating cash flow −$49.4M. The chart follows the revenue to costs, profit and cash.
Kyntra Bio (KYNB) · Q1 2026
Kyntra Bio, Q1 2026: revenue $3.7M (+36% year over year), operating margin -369.7%, net loss $15.2M, operating cash flow −$13.9M. The chart follows the revenue to costs, profit and cash.
| Immunome (IMNM) | Kyntra Bio (KYNB) | |
|---|---|---|
| Latest quarter | Q2 2025 | Q1 2026 |
| Revenue | $4.0M | $3.7M |
| Revenue growth, Y/Y | +70% | +36% |
| Operating margin | n/m | -369.7% |
| Net earnings | −$43.4M | −$15.2M |
| Net margin | — | -406.6% |
| Operating cash flow | −$49.4M | −$13.9M |
Where the revenue comes from
Kyntra Bio
- Drug Product Revenue: $3.5M (93%)
- Development and Other Revenue: $246K (7%)
Questions
Which is bigger, Immunome or Kyntra Bio?
Immunome is the larger company: $4.0M of revenue in its latest quarter (Q2 2025) against $3.7M for Kyntra Bio (Q1 2026).
Is Immunome or Kyntra Bio growing faster?
Immunome is growing faster (+70% against +36% a year earlier).
More: Immunome earnings · how Immunome makes money · Kyntra Bio earnings · how Kyntra Bio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2025; 10-Q filed May 12, 2026). Fiscal quarters can end on different dates. Not investment advice.